Additional renoprotective effect of the SGLT2 inhibitor dapagliflozin in a patient with ADPKD receiving tolvaptan treatment
Shun Minatoguchi, Hiroki Hayashi, Ryosuke Umeda, Shigehisa Koide, Midori Hasegawa, Naotake Tsuboi
Topics & Concepts
TolvaptanMedicineDapagliflozinAutosomal dominant polycystic kidney diseaseUrologyInternal medicineNephrologyKidney diseaseVasopressinRenal functionVasopressin AntagonistsEndocrinologyKidneyDiabetes mellitusAntagonistType 2 diabetesReceptorDiabetes Treatment and ManagementPancreatic function and diabetesGenetic and Kidney Cyst Diseases